Login / Signup

Editorial: intravenous to subcutaneous vedolizumab-switch without glitch! Authors' reply.

Viktoria BergqvistJohanna HolmgrenDaniel KlintmanJan Marsal
Published in: Alimentary pharmacology & therapeutics (2022)
Keyphrases
  • ulcerative colitis
  • patients with inflammatory bowel disease
  • high dose
  • low dose